Cefadroxil
- Generic Name
- Cefadroxil
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O5S
- CAS Number
- 50370-12-2
- Unique Ingredient Identifier
- Q525PA8JJB
- Background
Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
- Indication
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
- Associated Conditions
- Bacterial Infections, Infection and inflammatory reaction due to internal prosthetic device, implant, and graft, Skin and Subcutaneous Tissue Bacterial Infections, Streptococcal Pharyngitis, Tonsillitis streptococcal, Urinary Tract Infection
Cefadroxil 500 mg Capsules Under Fasting Conditions
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: DURICEF® capsules 500 mg
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 26
- Registration Number
- NCT00834275
- Locations
- 🇺🇸
Bioassay Laboratory, Inc., Houston, Texas, United States
🇨🇦Biovail Contract Research, Toronto, Ontario, Canada
Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding
Not Applicable
Completed
- Conditions
- Mastitis
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Karlstad University
- Target Recruit Count
- 210
- Registration Number
- NCT00405158
- Locations
- 🇸🇪
Dept Obstetrics & Gynecology, Helsingborg Hospital, Helsingborg, Skane, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath